Multiresistent tuberculosis: the third pandemic?
Keywords:
HIV, tuberculosis, multidrug resistance, nosocomial transmissionAbstract
The authors describe their recent experience with single and multidrug resistant tuberculo sis, associated with HIV infection. They emphasize particularly, the dimensions and gravity of this problem, for institutions and Public Health.
Downloads
References
Hannan M, Yates M, Gascoyne, Hinzi D et al. From Lisbon to London: the molecular epidemiology, investigations and infection control aspects of an out break of multidrug resistant tuberculosis in a London teaching hospital. - Abst. em 17th National Congress of the European Society of Micro biology, Paris, Junho l 996, pág. 46.
Easterhook P. Bell A, Hannan M et al. Nosocomial outbreak of multidrug resistant tuberculosis in a London HIV unit: out break investigation and clinical follow-up. Abst. em XI International Conference on Aids, Vancouver. July 10, 1996, pág. 25.
Hannan M. Bell A, Gascoyne, Binzi D et al. An outbreak of multidrug resistam tuberculosis ( MDRT) in a London teaching hospital HIV unit: outbreak investigations, infection control issues and molecular epidemiology. Abst. 7th International Congress for Infectious Diseases, Hong - Kong, June 10 - 13, 1996, pág. 212.
Nardell E and Brickner P. Tuherculosis in New York City - focal transmission of na often fatal disease. JAMA 1996; 276( 15): 1259 - 1260.
Frieden T, Sherman L et al. A multi-institutional outbreak of highly drug-resistant tuberculosis - epidemiology and clinical outcomes. JAMA 1996; 27605): 1259-1260.
Couldwell DL, Dore G et ai. Nosocomial outbreak of tuberculosis in na outpatient HIV treatment room. AIDS 1996; 10(5): 521-525.
Maltez F, Peres H, Machado J. et al. Multidrug resistant tuberculosis and HIV infection. Abst. em 7th International Congress for lnfectious Diseases, Hong-Kong,June 10-13, 1996, pág. 61.
Maltez F. MachadoJ, Peres H, Morgado A, Proença R. Tuherculose multiresistente e infeoção pelo VIH. Abst. em III Congresso Nacional sobre Sida, Porto, 7 - 10 Maio, 1997, pág. 48.
Antunes ML, Antunes FA. The tuberculosis situation in Portugal: a historical perspective to 1994. European communicable disease hulletin. Vol I, nª 3 September 1996.
Sudre P, Hirschel B, Gatel J et al. Tuberculosis among Europe an patient with the acquired immune deficiency syndrome. Tubercle and Lung disease 1996; 77: 322-328.
Raviglione M, Snider E, Kochi A. Global Epidemiology of tuberculosis - Morbiclity and Mortality of a worlwide epidemie. ]AMA 1995; 273 (53) 220 - 226.
OMS. Tuberculosis as an Aids-defining disease in Europe - HIV/ Aids Surveillance in Europe, n" 46, June 1995.
OMS - HIV testing and Surveillance among tuberculosis patients and tuberculosis prevention in HIV infected persons in Europe - HIV/Aids Surveillance in Europe, nº 46, June 1995
Wenger P. OnenJ, Hreeden A, Orfas D, Beck-Sague C, Jarvis W. Control of nosocomial transmission of multidrug resistant Mycobacterium tuberculosis among healthcare workers and HIV infected patients. Lancet 1995; 345: 235 - 240.
From CDC Tuberculosis Morhidity - United Stales, 1996. JAMA 1996: 275 (21 ): 1625- 1630.
Culliton B. Drug resistant TB may bring epidemie. Nature 1992: 356: 473
Bates. J, Nardell I. lnstitutional control measures for tuberculosis in the era of multidrug resistance. Chest 1995. 108: 1690-1710.
Maloney S. Pierson M, Gordon M, Del Castillo R. Boyle J, Jarvis W. Efficacy of control measures in preventing nosocomial transmission of multidrug - resistant tuberculosis of patients and Health care workers. Ann Intern Med 1995; 122: 90 - 95
Jarvis W, Bolyard F, Bozzi C and al. Respirators, recomendations and regulations: the controversy surrounding protection of health care workers from tuberculosis. An lntern Medicine 1995; 122(2): 142- 146.
Brubacher J and Hoffman R. Hazards of ultraviolet lighting used for tuberculosis control. Chest 1996; 109 ( 2): 582-583
National Action Plan to combat Multidrug resistant tuberculosis. MMWR 1992: 41 - no RR - 11
Rastogi N. Emergence of multiple drug resistant tuberculosis: fundamental and applied research aspects, global issues and current strategies. Res Microbiolog 1993; 144, 103 - 158.
De Cock K, Wilkinson D. Tuberculosis control in resource - poor countries: alternative approaches in the era of HIV. Lancet 1995: 346: 675 - 677.
De Cock K, Grant A, Porter J. Preventive therapy for tuberculosis in HIV infected persons: international recommendations. research. and practice. Lancet l 995: 545: 833-836
Haas C, Le Dinh C. Lowenstein W, Durand H. La tuberculose d:ms un service de médicine interne parisien - 50 ohservations. l'resse Médicale 1995: 24(:19): 1911.
Chaulk C. Chaisson R, Lewis J, Rizzo R. - Treating Multidrug resistant tuberculosis, compliance and side efects. JAMA 1994; 271(2):101- 104.
Meeting the challenge of multidrug - resistant tuberculosis: Summary of a Conference. MMWR, June 19. 1992. Vol. 41. NºRR-11.
Rodrigues L. BCG revacination against tuberculosis. Lancet 1996: 348 611.
Fox J. Coalition reacts to surge of Drug - resistant Tl:l. ASM news 1992:'i8(3): 135 - 1.39.
Brausch L, and Bass .J. The treatment of tuberculosis. Medical Clinics of North America 1993; 77(6): 1277 - 1288.
Pozsik C. Compliance with tuberculosis therapy Medical Clinics of North America 1993; 77(6):1289 - 1501.
From CDC - Tuberculosis Morbidity - United States. 1994..JAMA 1995; 274(10): 788 - 789.
Rom WN, Garay SM. Tuberculosis - Little Brown Company. ed. 1996
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
